You are here: Industry Insights > Market News > Covaxin may get launched in February 2021: ICMR scientist

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

NERVONIC ACID

百靈威J&K 降冰片烯 175425

百靈威J&K 三(3-羥基丙基)膦

百靈威J&K 三正辛基氧化膦 318216

百靈威J&K 三(2-羧乙基)膦鹽酸鹽 312334

百靈威J&K 4,5-雙二苯基膦-9,9-二甲基氧雜蒽 134853

Covaxin may get launched in February 2021: ICMR scientist

expresspharmaNovember 06, 2020

Tag: Covaxin , ICMR , COVID-19 , Bharat Biotech

Favorites

Bharat Biotech may launch COVAXIN as early as February – months earlier than expected – as last-stage trials begin this month and studies have so far shown it is safe and effective, a scientist from ICMR told Reuters.

The company had earlier hoped to launch it only in the second quarter of next year.

“The vaccine has shown good efficacy,” said Rajni Kant, senior ICMR scientist, who is also a member of its COVID-19 task-force.

“It is expected that by the beginning of next year, February or March, something would be available.”

Bharat Biotech could not immediately be contacted.

Previous:Dr Harsh Vardhan gives away Gandhian Young Technological Awards in two categories

Next:DoP forms expert committee to identify investment opportunities, bottlenecks in pharma industry

Alzheimer’s Disease: Charting the Course from Plaques to Promise

Muhammad Farhan KhalidMay 28, 2025

New Tools，New Hope，New Frontier

InnoCare Announces First Patient Dosed in the Phase II/IIII Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Vitiligo in China

PharmaSourcesMay 16, 2025

The Phase 3 Clinical Trial of Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic ?Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS

PR NewswireMay 12, 2025

Covaxin may get launched in February 2021: ICMR scientist | Pharmasources.com

Illuccix China Phase 3 Study Completes Enrolment

PR NewswireMay 13, 2025

Telix Pharmaceuticals Limited announces that the pivotal Phase 3 registration study of TLX591-CDx for prostate cancer imaging in Chinese patients has completed patient enrolment.